Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma

Trial Profile

PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Nivolumab (Primary) ; Pelareorep (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2018 According to an Oncolytics Biotech media release, first patient was treated in this trial.
    • 26 Oct 2018 Planned End Date changed from 31 Jul 2025 to 31 Oct 2024.
    • 26 Oct 2018 Planned primary completion date changed from 31 Jul 2022 to 31 Oct 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top